Search jobs 15-Apr-2021 OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers THE ONCOFOLLOW™ TESTS WILL HELP MONITOR DISEASE PROGRESSION IN PATIENTS UNDER TREATMENT WITHIN THE SCANDARE STUDY OncoDNA, a theranostic and genomic company specializing in precision medicine, announced the launch of a research project in collaboration with the French foundation for cancer research Institut Curie. The objective of this project is to assess the clinical utility of liquid biopsy for head and neck cancer patient monitoring. Initiated in 2016 by Institut Curie, the SCANDARE study aims to incorporate new dimensions to precision medicine. SCANDARE consists of integrating microenvironment and immune parameters into the analysis of a tumor along with the molecular alterations of the tumor. As part of the study, Institut Curie has teamed up with OncoDNA to evaluate the utility of liquid biopsy as a tool to monitor disease progression in patients treated for head and neck cancer.